Skip to main content
Premium Trial:

Request an Annual Quote

Joint Genome Institute, Enzo Life Sciences

Premium

This article has been updated to correct information about Enzo Biochem's BioArray CGH Labeling System.

The US Department of Energy's Joint Genome Institute has added 46 genomes to its Integrated Microbial Genomes data management system, bringing to 337 the total number of publicly available genomes, the JGI said last week.

IMG version 1.1 now includes 301 bacterial, 25 archaeal, and 11 eukaryotic genomes. Several new features have also been added to the IMG's genome analysis tools, including a function to compare gene occurrence profiles across organisms, an enhanced support infrastructure for comparing organism statistics, and the ability to save and load organism and gene analysis settings from local user files, according to the organization.

The data management system is updated on a quarterly basis and is scheduled to receive another upgrade at the beginning of September, the JGI said.


Enzo Life Sciences, a subsidiary of Enzo Biochem, last week launched its BioArray CGH Labeling System for array comparative genomic hybridization.

The system is "fully comprehensive" according to Enzo, and includes Cy3- and Cy5-labeled deoxynucleotides, as well as reagents and primers.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.